Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors
AbstractPancreatic cancer is a disease with remarkably poor patient survival rates. The frequent presence of metastases and profound chemoresistance pose a severe problem for the treatment of these tumors. Moreover, cross-talk between the tumor and the local micro-environment contributes to tumorigenicity, metastasis and chemoresistance. Compared to bulk tumor cells, cancer stem cells (CSC) have reduced sensitivity to chemotherapy. CSC are tumor cells with stem-like features that possess the ability to self-renew, but can also give rise to more differentiated progeny. CSC can be identified based on increased in vitro spheroid- or colony formation, enhanced in vivo tumor initiating potential, or expression of cell surface markers. Since CSC are thought to be required for the maintenance of a tumor cell population, these cells could possibly serve as a therapeutic target. There appears to be a causal relationship between CSC and epithelial-to-mesenchymal transition (EMT) in pancreatic tumors. The occurrence of EMT in pancreatic cancer cells is often accompanied by re-activation of developmental pathways, such as the Hedgehog, WNT, NOTCH, and Nodal/Activin pathways. Therapeutics based on CSC markers, EMT, developmental pathways, or tumor micro-environment could potentially be used to target pancreatic CSC. This may lead to a reduction of tumor growth, metastatic events, and chemoresistance in pancreatic cancer. View Full-Text
Share & Cite This Article
Hindriksen, S.; Bijlsma, M.F. Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. Cancers 2012, 4, 989-1035.
Hindriksen S, Bijlsma MF. Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. Cancers. 2012; 4(4):989-1035.Chicago/Turabian Style
Hindriksen, Sanne; Bijlsma, Maarten F. 2012. "Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors." Cancers 4, no. 4: 989-1035.